TY  - JOUR
AU  - Cirković, Andja
AU  - Stanisavljević, Dejana
AU  - Milin-Lazović, Jelena
AU  - Rajović, Nina
AU  - Pavlović, Vedrana
AU  - Milicević, Ognjen
AU  - Savić, Marko
AU  - Perić, Jelena
AU  - Aleksić, Nataša
AU  - Milić, Nikola
AU  - Stanisavljević, Tamara
AU  - Miković, Zeljko
AU  - Garović, Vesna
AU  - Milić, Nataša
PY  - 2021
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1430
AB  - Introduction: Preeclampsia (PE) is a pregnancy-associated, multi-organ, life-threatening disease that appears after the 20th week of gestation. The aim of this study was to perform a systematic review and meta-analysis to determine whether women with PE have disrupted miRNA expression compared to women who do not have PE.Methods: We conducted a systematic review and meta-analysis of studies that reported miRNAs expression levels in placenta or peripheral blood of pregnant women with vs. without PE. Studies published before October 29, 2021 were identified through PubMed, EMBASE and Web of Science. Two reviewers used predefined forms and protocols to evaluate independently the eligibility of studies based on titles and abstracts and to perform full-text screening, data abstraction and quality assessment. Standardized mean difference (SMD) was used as a measure of effect size.Results: 229 publications were included in the systematic review and 53 in the meta-analysis. The expression levels in placenta were significantly higher in women with PE compared to women without PE for miRNA-16 (SMD = 1.51,95%CI = 0.55-2.46), miRNA-20b (SMD = 0.89, 95%CI = 0.33-1.45), miRNA-23a (SMD = 2.02, 95%CI = 1.25-2.78), miRNA-29b (SMD = 1.37, 95%CI = 0.36-2.37), miRNA-155 (SMD = 2.99, 95%CI = 0.83-5.14) and miRNA-210 (SMD = 1.63, 95%CI = 0.69-2.58), and significantly lower for miRNA-376c (SMD = -4.86, 95%CI = -9.51 to -0.20). An increased level of miRNK-155 expression was found in peripheral blood of women with PE (SMD = 2.06, 95%CI = 0.35-3.76), while the expression level of miRNA-16 was significantly lower in peripheral blood of PE women (SMD = -0.47, 95%CI = -0.91 to -0.03). The functional roles of the presented miRNAs include control of trophoblast proliferation, migration, invasion, apoptosis, differentiation, cellular metabolism and angiogenesis.Conclusion: miRNAs play an important role in the pathophysiology of PE. The identification of differentially expressed miRNAs in maternal blood creates an opportunity to define an easily accessible biomarker of PE.
PB  - Frontiers Media Sa, Lausanne
T2  - Frontiers in Bioengineering and Biotechnology
T1  - Preeclamptic Women Have Disrupted Placental microRNA Expression at the Time of Preeclampsia Diagnosis: Meta-Analysis
VL  - 9
DO  - 10.3389/fbioe.2021.782845
ER  - 

@article{
author = "Cirković, Andja and Stanisavljević, Dejana and Milin-Lazović, Jelena and Rajović, Nina and Pavlović, Vedrana and Milicević, Ognjen and Savić, Marko and Perić, Jelena and Aleksić, Nataša and Milić, Nikola and Stanisavljević, Tamara and Miković, Zeljko and Garović, Vesna and Milić, Nataša",
year = "2021",
abstract = "Introduction: Preeclampsia (PE) is a pregnancy-associated, multi-organ, life-threatening disease that appears after the 20th week of gestation. The aim of this study was to perform a systematic review and meta-analysis to determine whether women with PE have disrupted miRNA expression compared to women who do not have PE.Methods: We conducted a systematic review and meta-analysis of studies that reported miRNAs expression levels in placenta or peripheral blood of pregnant women with vs. without PE. Studies published before October 29, 2021 were identified through PubMed, EMBASE and Web of Science. Two reviewers used predefined forms and protocols to evaluate independently the eligibility of studies based on titles and abstracts and to perform full-text screening, data abstraction and quality assessment. Standardized mean difference (SMD) was used as a measure of effect size.Results: 229 publications were included in the systematic review and 53 in the meta-analysis. The expression levels in placenta were significantly higher in women with PE compared to women without PE for miRNA-16 (SMD = 1.51,95%CI = 0.55-2.46), miRNA-20b (SMD = 0.89, 95%CI = 0.33-1.45), miRNA-23a (SMD = 2.02, 95%CI = 1.25-2.78), miRNA-29b (SMD = 1.37, 95%CI = 0.36-2.37), miRNA-155 (SMD = 2.99, 95%CI = 0.83-5.14) and miRNA-210 (SMD = 1.63, 95%CI = 0.69-2.58), and significantly lower for miRNA-376c (SMD = -4.86, 95%CI = -9.51 to -0.20). An increased level of miRNK-155 expression was found in peripheral blood of women with PE (SMD = 2.06, 95%CI = 0.35-3.76), while the expression level of miRNA-16 was significantly lower in peripheral blood of PE women (SMD = -0.47, 95%CI = -0.91 to -0.03). The functional roles of the presented miRNAs include control of trophoblast proliferation, migration, invasion, apoptosis, differentiation, cellular metabolism and angiogenesis.Conclusion: miRNAs play an important role in the pathophysiology of PE. The identification of differentially expressed miRNAs in maternal blood creates an opportunity to define an easily accessible biomarker of PE.",
publisher = "Frontiers Media Sa, Lausanne",
journal = "Frontiers in Bioengineering and Biotechnology",
title = "Preeclamptic Women Have Disrupted Placental microRNA Expression at the Time of Preeclampsia Diagnosis: Meta-Analysis",
volume = "9",
doi = "10.3389/fbioe.2021.782845"
}

Cirković, A., Stanisavljević, D., Milin-Lazović, J., Rajović, N., Pavlović, V., Milicević, O., Savić, M., Perić, J., Aleksić, N., Milić, N., Stanisavljević, T., Miković, Z., Garović, V.,& Milić, N.. (2021). Preeclamptic Women Have Disrupted Placental microRNA Expression at the Time of Preeclampsia Diagnosis: Meta-Analysis. in Frontiers in Bioengineering and Biotechnology
Frontiers Media Sa, Lausanne., 9.
https://doi.org/10.3389/fbioe.2021.782845

Cirković A, Stanisavljević D, Milin-Lazović J, Rajović N, Pavlović V, Milicević O, Savić M, Perić J, Aleksić N, Milić N, Stanisavljević T, Miković Z, Garović V, Milić N. Preeclamptic Women Have Disrupted Placental microRNA Expression at the Time of Preeclampsia Diagnosis: Meta-Analysis. in Frontiers in Bioengineering and Biotechnology. 2021;9.
doi:10.3389/fbioe.2021.782845 .

Cirković, Andja, Stanisavljević, Dejana, Milin-Lazović, Jelena, Rajović, Nina, Pavlović, Vedrana, Milicević, Ognjen, Savić, Marko, Perić, Jelena, Aleksić, Nataša, Milić, Nikola, Stanisavljević, Tamara, Miković, Zeljko, Garović, Vesna, Milić, Nataša, "Preeclamptic Women Have Disrupted Placental microRNA Expression at the Time of Preeclampsia Diagnosis: Meta-Analysis" in Frontiers in Bioengineering and Biotechnology, 9 (2021),
https://doi.org/10.3389/fbioe.2021.782845 . .

TY  - JOUR
AU  - Lalić-Cosić, Sanja
AU  - Dopsaj, Violeta
AU  - Kovač, Mirjana
AU  - Pruner, Iva
AU  - Littmann, Karin
AU  - Mandić-Marković, Vesna
AU  - Miković, Zeljko
AU  - Antović, Aleksandra
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1390
AB  - Introduction Haemostatic balance shifted towards hypercoagulability in normal pregnancy is even more pronounced in pre-eclampsia (P-EC). The aim of this study was to analyse haemostatic disturbances and fibrin clot properties in women with pre-eclampsia and to investigate their association with maternal and foetal outcomes. Methods Forty-six pregnant women diagnosed with pre-eclampsia were included in the study, with blood sampling done on the morning following admission to hospital, as well as after delivery (mean duration 4.8 days). Two global haemostatic assays-endogenous thrombin potential (ETP) and assay of overall haemostatic potential (OHP)-were employed, including fibrin clot turbidity measurements and scanning electron microscopy (SEM) of representative samples. Results Three thrombin generation parameters (ETP, t_lag and peak height) and OHP were significantly increased in pre-eclampsia compared with controls, whereas overall fibrinolytic potential (OFP-determined as a parameter of the OHP assay) had significantly lower values. Clot lysis time was significantly prolonged in patients with pre-eclampsia. In the pre-eclamptic group after delivery, we observed a significant elevation in the peak height and a reduction in the time to peak and OFP compared with values before delivery. Pre-eclamptic patients with renal complications had significantly higher values for ETP, peak height and D-dimer. Turbidity measurements and SEM revealed dense fibrin structure in patients with pre-eclampsia. Conclusion Patients with pre-eclampsia have enhanced coagulation and impaired fibrinolysis before, and even after, delivery. In particular, the presence of multi-organ dysfunction, such as renal dysfunction, may be associated with increased thrombin generation in pre-eclampsia.
PB  - Wiley, Hoboken
T2  - International Journal of Laboratory Hematology
T1  - Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia
EP  - 330
IS  - 3
SP  - 322
VL  - 42
DO  - 10.1111/ijlh.13183
ER  - 

@article{
author = "Lalić-Cosić, Sanja and Dopsaj, Violeta and Kovač, Mirjana and Pruner, Iva and Littmann, Karin and Mandić-Marković, Vesna and Miković, Zeljko and Antović, Aleksandra",
year = "2020",
abstract = "Introduction Haemostatic balance shifted towards hypercoagulability in normal pregnancy is even more pronounced in pre-eclampsia (P-EC). The aim of this study was to analyse haemostatic disturbances and fibrin clot properties in women with pre-eclampsia and to investigate their association with maternal and foetal outcomes. Methods Forty-six pregnant women diagnosed with pre-eclampsia were included in the study, with blood sampling done on the morning following admission to hospital, as well as after delivery (mean duration 4.8 days). Two global haemostatic assays-endogenous thrombin potential (ETP) and assay of overall haemostatic potential (OHP)-were employed, including fibrin clot turbidity measurements and scanning electron microscopy (SEM) of representative samples. Results Three thrombin generation parameters (ETP, t_lag and peak height) and OHP were significantly increased in pre-eclampsia compared with controls, whereas overall fibrinolytic potential (OFP-determined as a parameter of the OHP assay) had significantly lower values. Clot lysis time was significantly prolonged in patients with pre-eclampsia. In the pre-eclamptic group after delivery, we observed a significant elevation in the peak height and a reduction in the time to peak and OFP compared with values before delivery. Pre-eclamptic patients with renal complications had significantly higher values for ETP, peak height and D-dimer. Turbidity measurements and SEM revealed dense fibrin structure in patients with pre-eclampsia. Conclusion Patients with pre-eclampsia have enhanced coagulation and impaired fibrinolysis before, and even after, delivery. In particular, the presence of multi-organ dysfunction, such as renal dysfunction, may be associated with increased thrombin generation in pre-eclampsia.",
publisher = "Wiley, Hoboken",
journal = "International Journal of Laboratory Hematology",
title = "Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia",
pages = "330-322",
number = "3",
volume = "42",
doi = "10.1111/ijlh.13183"
}

Lalić-Cosić, S., Dopsaj, V., Kovač, M., Pruner, I., Littmann, K., Mandić-Marković, V., Miković, Z.,& Antović, A.. (2020). Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia. in International Journal of Laboratory Hematology
Wiley, Hoboken., 42(3), 322-330.
https://doi.org/10.1111/ijlh.13183

Lalić-Cosić S, Dopsaj V, Kovač M, Pruner I, Littmann K, Mandić-Marković V, Miković Z, Antović A. Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia. in International Journal of Laboratory Hematology. 2020;42(3):322-330.
doi:10.1111/ijlh.13183 .

Lalić-Cosić, Sanja, Dopsaj, Violeta, Kovač, Mirjana, Pruner, Iva, Littmann, Karin, Mandić-Marković, Vesna, Miković, Zeljko, Antović, Aleksandra, "Evaluation of global haemostatic assays and fibrin structure in patients with pre-eclampsia" in International Journal of Laboratory Hematology, 42, no. 3 (2020):322-330,
https://doi.org/10.1111/ijlh.13183 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Miković, Zeljko
AU  - Mandić, Vesna
AU  - Miljić, Predrag
AU  - Mitrović, Mirjana
AU  - Tomić, Branko
AU  - Bereczky, Zsuzsanna
PY  - 2019
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1287
AB  - Background: Inherited antithrombin (AT) deficiency is a rare autosomal dominant disorder, caused by mutations in the SERPINC1 gene. The most common clinical presentation in AT deficient patients includes venous thrombosis and pulmonary embolism, while the association of AT deficiency and its effect on the development of pregnancy complications has been less studied. The aim of our research was to evaluate the effect of AT deficiency types, determined by genotyping, on pregnancy outcomes. Methods: A retrospective cohort study included 28 women with AT deficiency, and their 64 pregnancies were analyzed. Results: With regard to live birth rate, a significant difference was observed among women who were carriers of different SERPINC1 mutations, as the rate varied from 100% in cases of type I to the extremely low rate of 8% for women with type II HBS (AT Budapest 3) in the homozygous variant, P=0.0005. All pregnancies from the type I group, even untreated ones, resulted in live births. In women with AT Budapest 3 in homozygous variant the overall live birth rate increased to 28.5% in the treated pregnancies. In this group the highest incidence of fetal death was observed of 62%; repeated fetal losses in 30%; fetal growth restriction in 22% and placental abruption in 7% of all pregnancies. Conclusion: Our study results indicate a difference between type I and type II AT deficiency. The risk of pregnancy related VTE was equally present in both groups, except for AT Budapest 3 in the heterozygous variant, while adverse pregnancy outcomes were strictly related to type II, especially AT Budapest 3 in the homozygous variant.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications
EP  - 19
SP  - 12
VL  - 173
DO  - 10.1016/j.thromres.2018.11.006
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Miković, Zeljko and Mandić, Vesna and Miljić, Predrag and Mitrović, Mirjana and Tomić, Branko and Bereczky, Zsuzsanna",
year = "2019",
abstract = "Background: Inherited antithrombin (AT) deficiency is a rare autosomal dominant disorder, caused by mutations in the SERPINC1 gene. The most common clinical presentation in AT deficient patients includes venous thrombosis and pulmonary embolism, while the association of AT deficiency and its effect on the development of pregnancy complications has been less studied. The aim of our research was to evaluate the effect of AT deficiency types, determined by genotyping, on pregnancy outcomes. Methods: A retrospective cohort study included 28 women with AT deficiency, and their 64 pregnancies were analyzed. Results: With regard to live birth rate, a significant difference was observed among women who were carriers of different SERPINC1 mutations, as the rate varied from 100% in cases of type I to the extremely low rate of 8% for women with type II HBS (AT Budapest 3) in the homozygous variant, P=0.0005. All pregnancies from the type I group, even untreated ones, resulted in live births. In women with AT Budapest 3 in homozygous variant the overall live birth rate increased to 28.5% in the treated pregnancies. In this group the highest incidence of fetal death was observed of 62%; repeated fetal losses in 30%; fetal growth restriction in 22% and placental abruption in 7% of all pregnancies. Conclusion: Our study results indicate a difference between type I and type II AT deficiency. The risk of pregnancy related VTE was equally present in both groups, except for AT Budapest 3 in the heterozygous variant, while adverse pregnancy outcomes were strictly related to type II, especially AT Budapest 3 in the homozygous variant.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications",
pages = "19-12",
volume = "173",
doi = "10.1016/j.thromres.2018.11.006"
}

Kovač, M., Mitić, G., Miković, Z., Mandić, V., Miljić, P., Mitrović, M., Tomić, B.,& Bereczky, Z.. (2019). The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 173, 12-19.
https://doi.org/10.1016/j.thromres.2018.11.006

Kovač M, Mitić G, Miković Z, Mandić V, Miljić P, Mitrović M, Tomić B, Bereczky Z. The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications. in Thrombosis Research. 2019;173:12-19.
doi:10.1016/j.thromres.2018.11.006 .

Kovač, Mirjana, Mitić, Gorana, Miković, Zeljko, Mandić, Vesna, Miljić, Predrag, Mitrović, Mirjana, Tomić, Branko, Bereczky, Zsuzsanna, "The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications" in Thrombosis Research, 173 (2019):12-19,
https://doi.org/10.1016/j.thromres.2018.11.006 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Miković, Zeljko
AU  - Mandić, Vesna
AU  - Đorđević, Valentina
AU  - Muszbek, Laszlo
AU  - Bereczky, Zsuzsanna
PY  - 2016
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/990
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency
EP  - 113
SP  - 111
VL  - 139
DO  - 10.1016/j.thromres.2016.01.018
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Miković, Zeljko and Mandić, Vesna and Đorđević, Valentina and Muszbek, Laszlo and Bereczky, Zsuzsanna",
year = "2016",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency",
pages = "113-111",
volume = "139",
doi = "10.1016/j.thromres.2016.01.018"
}

Kovač, M., Mitić, G., Miković, Z., Mandić, V., Đorđević, V., Muszbek, L.,& Bereczky, Z.. (2016). Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 139, 111-113.
https://doi.org/10.1016/j.thromres.2016.01.018

Kovač M, Mitić G, Miković Z, Mandić V, Đorđević V, Muszbek L, Bereczky Z. Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency. in Thrombosis Research. 2016;139:111-113.
doi:10.1016/j.thromres.2016.01.018 .

Kovač, Mirjana, Mitić, Gorana, Miković, Zeljko, Mandić, Vesna, Đorđević, Valentina, Muszbek, Laszlo, Bereczky, Zsuzsanna, "Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency" in Thrombosis Research, 139 (2016):111-113,
https://doi.org/10.1016/j.thromres.2016.01.018 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Elezović, Ivo
AU  - Miković, Zeljko
AU  - Mandić, Vesna
AU  - Đorđević, Valentina
AU  - Radojković, Dragica
AU  - Lalić-Cosić, Sanja
AU  - Murata, Moe
AU  - Takagi, Akira
AU  - Kojima, Tetsuhito
PY  - 2015
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/853
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - High prophylactic LMWH dose successfully suppressed hemostatic activation in pregnant woman with a new prothrombin c.1787G  gt  Amutation
EP  - 422
IS  - 2
SP  - 420
VL  - 135
DO  - 10.1016/j.thromres.2014.12.008
ER  - 

@article{
author = "Kovač, Mirjana and Elezović, Ivo and Miković, Zeljko and Mandić, Vesna and Đorđević, Valentina and Radojković, Dragica and Lalić-Cosić, Sanja and Murata, Moe and Takagi, Akira and Kojima, Tetsuhito",
year = "2015",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "High prophylactic LMWH dose successfully suppressed hemostatic activation in pregnant woman with a new prothrombin c.1787G  gt  Amutation",
pages = "422-420",
number = "2",
volume = "135",
doi = "10.1016/j.thromres.2014.12.008"
}

Kovač, M., Elezović, I., Miković, Z., Mandić, V., Đorđević, V., Radojković, D., Lalić-Cosić, S., Murata, M., Takagi, A.,& Kojima, T.. (2015). High prophylactic LMWH dose successfully suppressed hemostatic activation in pregnant woman with a new prothrombin c.1787G  gt  Amutation. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 135(2), 420-422.
https://doi.org/10.1016/j.thromres.2014.12.008

Kovač M, Elezović I, Miković Z, Mandić V, Đorđević V, Radojković D, Lalić-Cosić S, Murata M, Takagi A, Kojima T. High prophylactic LMWH dose successfully suppressed hemostatic activation in pregnant woman with a new prothrombin c.1787G  gt  Amutation. in Thrombosis Research. 2015;135(2):420-422.
doi:10.1016/j.thromres.2014.12.008 .

Kovač, Mirjana, Elezović, Ivo, Miković, Zeljko, Mandić, Vesna, Đorđević, Valentina, Radojković, Dragica, Lalić-Cosić, Sanja, Murata, Moe, Takagi, Akira, Kojima, Tetsuhito, "High prophylactic LMWH dose successfully suppressed hemostatic activation in pregnant woman with a new prothrombin c.1787G  gt  Amutation" in Thrombosis Research, 135, no. 2 (2015):420-422,
https://doi.org/10.1016/j.thromres.2014.12.008 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Miković, Zeljko
AU  - Mitić, Gorana
AU  - Đorđević, Valentina
AU  - Mandić, Vesna
AU  - Rakićević, Ljiljana
AU  - Radojković, Dragica
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/783
AB  - The study was conducted to evaluate the effect of anticoagulant therapy in women with thrombophilia and to detect the possible differences among carriers of mutations (factor V [FV] Leiden and FIIG20210) and those with natural anticoagulant deficiency. The 4-year prospective investigation included 85 pregnant women, with a history of recurrent fetal loss (RFL). They were treated with prophylactic doses of low-molecular-weight heparin (nadroparin) starting from 6 to 8 weeks of gestation. Pregnancy outcomes were evaluated based on the thrombophilia type. Carriers of thrombophilic mutations had a live birth rate of 93%, compared to 41.6% for women with natural anticoagulant deficiencies. Significant differences between the groups were also observed for intrauterine fetal death, intrauterine growth restriction, and postpartum thrombosis. The optimal therapy for women with natural anticoagulant deficiency and RFL remains unclear and future prospective study with a large number of patients is required to determine the best treatment for these severe thrombophilic conditions.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Clinical and Applied Thrombosis-Hemostasis
T1  - Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?
EP  - 189
IS  - 2
SP  - 184
VL  - 20
DO  - 10.1177/1076029612468940
ER  - 

@article{
author = "Kovač, Mirjana and Miković, Zeljko and Mitić, Gorana and Đorđević, Valentina and Mandić, Vesna and Rakićević, Ljiljana and Radojković, Dragica",
year = "2014",
abstract = "The study was conducted to evaluate the effect of anticoagulant therapy in women with thrombophilia and to detect the possible differences among carriers of mutations (factor V [FV] Leiden and FIIG20210) and those with natural anticoagulant deficiency. The 4-year prospective investigation included 85 pregnant women, with a history of recurrent fetal loss (RFL). They were treated with prophylactic doses of low-molecular-weight heparin (nadroparin) starting from 6 to 8 weeks of gestation. Pregnancy outcomes were evaluated based on the thrombophilia type. Carriers of thrombophilic mutations had a live birth rate of 93%, compared to 41.6% for women with natural anticoagulant deficiencies. Significant differences between the groups were also observed for intrauterine fetal death, intrauterine growth restriction, and postpartum thrombosis. The optimal therapy for women with natural anticoagulant deficiency and RFL remains unclear and future prospective study with a large number of patients is required to determine the best treatment for these severe thrombophilic conditions.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Clinical and Applied Thrombosis-Hemostasis",
title = "Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?",
pages = "189-184",
number = "2",
volume = "20",
doi = "10.1177/1076029612468940"
}

Kovač, M., Miković, Z., Mitić, G., Đorđević, V., Mandić, V., Rakićević, L.,& Radojković, D.. (2014). Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?. in Clinical and Applied Thrombosis-Hemostasis
Sage Publications Inc, Thousand Oaks., 20(2), 184-189.
https://doi.org/10.1177/1076029612468940

Kovač M, Miković Z, Mitić G, Đorđević V, Mandić V, Rakićević L, Radojković D. Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?. in Clinical and Applied Thrombosis-Hemostasis. 2014;20(2):184-189.
doi:10.1177/1076029612468940 .

Kovač, Mirjana, Miković, Zeljko, Mitić, Gorana, Đorđević, Valentina, Mandić, Vesna, Rakićević, Ljiljana, Radojković, Dragica, "Does Anticoagulant Therapy Improve Pregnancy Outcome Equally, Regardless of Specific Thrombophilia Type?" in Clinical and Applied Thrombosis-Hemostasis, 20, no. 2 (2014):184-189,
https://doi.org/10.1177/1076029612468940 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Miljić, Predrag
AU  - Miković, Zeljko
AU  - Mandić, Vesna
AU  - Đorđević, Valentina
AU  - Radojković, Dragica
AU  - Bereczky, Zsuzsanna
AU  - Muszbek, Laszlo
PY  - 2014
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/722
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Thrombosis Research
T1  - Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency
EP  - 1160
IS  - 6
SP  - 1158
VL  - 133
DO  - 10.1016/j.thromres.2014.03.025
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Miljić, Predrag and Miković, Zeljko and Mandić, Vesna and Đorđević, Valentina and Radojković, Dragica and Bereczky, Zsuzsanna and Muszbek, Laszlo",
year = "2014",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Thrombosis Research",
title = "Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency",
pages = "1160-1158",
number = "6",
volume = "133",
doi = "10.1016/j.thromres.2014.03.025"
}

Kovač, M., Mitić, G., Miljić, P., Miković, Z., Mandić, V., Đorđević, V., Radojković, D., Bereczky, Z.,& Muszbek, L.. (2014). Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency. in Thrombosis Research
Pergamon-Elsevier Science Ltd, Oxford., 133(6), 1158-1160.
https://doi.org/10.1016/j.thromres.2014.03.025

Kovač M, Mitić G, Miljić P, Miković Z, Mandić V, Đorđević V, Radojković D, Bereczky Z, Muszbek L. Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency. in Thrombosis Research. 2014;133(6):1158-1160.
doi:10.1016/j.thromres.2014.03.025 .

Kovač, Mirjana, Mitić, Gorana, Miljić, Predrag, Miković, Zeljko, Mandić, Vesna, Đorđević, Valentina, Radojković, Dragica, Bereczky, Zsuzsanna, Muszbek, Laszlo, "Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency" in Thrombosis Research, 133, no. 6 (2014):1158-1160,
https://doi.org/10.1016/j.thromres.2014.03.025 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Mitić, Gorana
AU  - Miković, Zeljko
AU  - Antonijević, Nebojša
AU  - Đorđević, Valentina
AU  - Miković, Danijela
AU  - Mandić, Vesna
AU  - Rakićević, Ljiljana
AU  - Radojković, Dragica
PY  - 2010
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/412
AB  - Factor V Leiden (FVLeiden) and prothrombin G20210A are the most common genetic causes of thrombophilia and established risk factors for different clinical manifestations of venous thromboembolism (VTE). This study investigated whether the clinical manifestation of VTE, the extension of deep vein thrombosis (DVT) and the presence of transient risk factors at the time of the first VTE, differed among patients with mutations (97 with FVLeiden; 33 with prothrombin G20210A) and in 109 patients without thrombophilia. Isolated pulmonary embolism (PE) was less prevalent in patients with FVLeiden (6%) and no thrombophilia (6%) than in those with prothrombin G20210A (15%). No difference was found in the incidence of distal DVT. Regarding the extension of proximal DVT, the lowest incidence for isolated popliteal vein and the highest for iliofemoral vein were observed in patients with prothrombin G20210A. No difference was observed between groups of patients with or without thrombophilia by unprovoked VTE. The pregnancy/puerperium was the most prevalent risk factor in carriers of prothrombin G20210A. Among FVLeiden carriers, the most prevalent risk factor was surgery, and in patients without thrombophilia, it was trauma (P  lt  .05). Thrombosis of the upper limb was more frequent in a group without thrombophilia than in patients with mutations (P  lt  .01). Transverse sinus venous thrombosis was present only in patients with prothrombin G20210A. Carriers of prothrombin G20210A have an increased risk of developing isolated PE and more severe clinical manifestations than those with FVLeiden or without thrombophilia.
PB  - Sage Publications Inc, Thousand Oaks
T2  - Clinical and Applied Thrombosis-Hemostasis
T1  - Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation
EP  - 70
IS  - 1
SP  - 66
VL  - 16
DO  - 10.1177/1076029608320721
ER  - 

@article{
author = "Kovač, Mirjana and Mitić, Gorana and Miković, Zeljko and Antonijević, Nebojša and Đorđević, Valentina and Miković, Danijela and Mandić, Vesna and Rakićević, Ljiljana and Radojković, Dragica",
year = "2010",
abstract = "Factor V Leiden (FVLeiden) and prothrombin G20210A are the most common genetic causes of thrombophilia and established risk factors for different clinical manifestations of venous thromboembolism (VTE). This study investigated whether the clinical manifestation of VTE, the extension of deep vein thrombosis (DVT) and the presence of transient risk factors at the time of the first VTE, differed among patients with mutations (97 with FVLeiden; 33 with prothrombin G20210A) and in 109 patients without thrombophilia. Isolated pulmonary embolism (PE) was less prevalent in patients with FVLeiden (6%) and no thrombophilia (6%) than in those with prothrombin G20210A (15%). No difference was found in the incidence of distal DVT. Regarding the extension of proximal DVT, the lowest incidence for isolated popliteal vein and the highest for iliofemoral vein were observed in patients with prothrombin G20210A. No difference was observed between groups of patients with or without thrombophilia by unprovoked VTE. The pregnancy/puerperium was the most prevalent risk factor in carriers of prothrombin G20210A. Among FVLeiden carriers, the most prevalent risk factor was surgery, and in patients without thrombophilia, it was trauma (P  lt  .05). Thrombosis of the upper limb was more frequent in a group without thrombophilia than in patients with mutations (P  lt  .01). Transverse sinus venous thrombosis was present only in patients with prothrombin G20210A. Carriers of prothrombin G20210A have an increased risk of developing isolated PE and more severe clinical manifestations than those with FVLeiden or without thrombophilia.",
publisher = "Sage Publications Inc, Thousand Oaks",
journal = "Clinical and Applied Thrombosis-Hemostasis",
title = "Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation",
pages = "70-66",
number = "1",
volume = "16",
doi = "10.1177/1076029608320721"
}

Kovač, M., Mitić, G., Miković, Z., Antonijević, N., Đorđević, V., Miković, D., Mandić, V., Rakićević, L.,& Radojković, D.. (2010). Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation. in Clinical and Applied Thrombosis-Hemostasis
Sage Publications Inc, Thousand Oaks., 16(1), 66-70.
https://doi.org/10.1177/1076029608320721

Kovač M, Mitić G, Miković Z, Antonijević N, Đorđević V, Miković D, Mandić V, Rakićević L, Radojković D. Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation. in Clinical and Applied Thrombosis-Hemostasis. 2010;16(1):66-70.
doi:10.1177/1076029608320721 .

Kovač, Mirjana, Mitić, Gorana, Miković, Zeljko, Antonijević, Nebojša, Đorđević, Valentina, Miković, Danijela, Mandić, Vesna, Rakićević, Ljiljana, Radojković, Dragica, "Type and Location of Venous Thromboembolism in Carriers of Factor V Leiden or Prothrombin G20210A Mutation Versus Patients With No Mutation" in Clinical and Applied Thrombosis-Hemostasis, 16, no. 1 (2010):66-70,
https://doi.org/10.1177/1076029608320721 . .

TY  - JOUR
AU  - Kovač, Mirjana
AU  - Miković, Zeljko
AU  - Rakićević, Ljiljana
AU  - Srzentić, Snežana
AU  - Mandić, Vesna
AU  - Đorđević, Valentina
AU  - Radojković, Dragica
AU  - Elezović, Ivo
PY  - 2010
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/413
AB  - Objective: D-dimer testing has an important role in the exclusion of acute venous thromboembolism (VTE) in the nonpregnant population. Establishing D-dimers role in the diagnosis of VTE in pregnancy is hampered because of the substantial increase of D-dimer throughout gestational age. Study design: In a prospective study we followed 89 healthy pregnant women to establish the reference range of D-dimer for each trimester. D-dimer testing was also performed in 12 women with clinical suspicion of VTE and their results were compared with the established new reference range of D-dimer, and with the recorded ultrasound findings. Results: In the first trimester, 84% women from reference group had normal D-dimer, in the second 33%, and by the third trimester only 1%, which suggests that D-dimer has no practical diagnostic use in ruling out VTE if the threshold of 230 ng/mL for abnormal is used. All pregnant women with thrombosis who had positive ultrasound findings also had statistically significant elevation of the D-dimer level, considering the established reference range of the corresponding trimester. We found 100% sensitivity of D-dimer test. A women developed thrombosis in the first trimester had 6.7-7.6 time higher level of D-dimer than the mean value in the reference group, and in the third trimester thrombotic women had 2.0-3.8 time higher level of D-dimer, p  lt  0.0001. Conclusion: D-dimer test with the new threshold for: the first of 286, the second of 457 and the third trimester of 644 ng/mL can be useful in diagnosis of pregnancy related VTE.
PB  - Elsevier, Amsterdam
T2  - European Journal of Obstetrics & Gynecology and Reproductive Biology
T1  - The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy
EP  - 30
IS  - 1
SP  - 27
VL  - 148
DO  - 10.1016/j.ejogrb.2009.09.005
ER  - 

@article{
author = "Kovač, Mirjana and Miković, Zeljko and Rakićević, Ljiljana and Srzentić, Snežana and Mandić, Vesna and Đorđević, Valentina and Radojković, Dragica and Elezović, Ivo",
year = "2010",
abstract = "Objective: D-dimer testing has an important role in the exclusion of acute venous thromboembolism (VTE) in the nonpregnant population. Establishing D-dimers role in the diagnosis of VTE in pregnancy is hampered because of the substantial increase of D-dimer throughout gestational age. Study design: In a prospective study we followed 89 healthy pregnant women to establish the reference range of D-dimer for each trimester. D-dimer testing was also performed in 12 women with clinical suspicion of VTE and their results were compared with the established new reference range of D-dimer, and with the recorded ultrasound findings. Results: In the first trimester, 84% women from reference group had normal D-dimer, in the second 33%, and by the third trimester only 1%, which suggests that D-dimer has no practical diagnostic use in ruling out VTE if the threshold of 230 ng/mL for abnormal is used. All pregnant women with thrombosis who had positive ultrasound findings also had statistically significant elevation of the D-dimer level, considering the established reference range of the corresponding trimester. We found 100% sensitivity of D-dimer test. A women developed thrombosis in the first trimester had 6.7-7.6 time higher level of D-dimer than the mean value in the reference group, and in the third trimester thrombotic women had 2.0-3.8 time higher level of D-dimer, p  lt  0.0001. Conclusion: D-dimer test with the new threshold for: the first of 286, the second of 457 and the third trimester of 644 ng/mL can be useful in diagnosis of pregnancy related VTE.",
publisher = "Elsevier, Amsterdam",
journal = "European Journal of Obstetrics & Gynecology and Reproductive Biology",
title = "The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy",
pages = "30-27",
number = "1",
volume = "148",
doi = "10.1016/j.ejogrb.2009.09.005"
}

Kovač, M., Miković, Z., Rakićević, L., Srzentić, S., Mandić, V., Đorđević, V., Radojković, D.,& Elezović, I.. (2010). The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy. in European Journal of Obstetrics & Gynecology and Reproductive Biology
Elsevier, Amsterdam., 148(1), 27-30.
https://doi.org/10.1016/j.ejogrb.2009.09.005

Kovač M, Miković Z, Rakićević L, Srzentić S, Mandić V, Đorđević V, Radojković D, Elezović I. The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy. in European Journal of Obstetrics & Gynecology and Reproductive Biology. 2010;148(1):27-30.
doi:10.1016/j.ejogrb.2009.09.005 .

Kovač, Mirjana, Miković, Zeljko, Rakićević, Ljiljana, Srzentić, Snežana, Mandić, Vesna, Đorđević, Valentina, Radojković, Dragica, Elezović, Ivo, "The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy" in European Journal of Obstetrics & Gynecology and Reproductive Biology, 148, no. 1 (2010):27-30,
https://doi.org/10.1016/j.ejogrb.2009.09.005 . .